P3–120RETROSPECTIVE ANALYSIS OF RE-CHALLENGE OF EGFR TK-IS IN PATIENTS WITH ADVANCED AND RECURRENT NON-SMALL CELL LUNG CANCER

Background: The efficacy of re-administration of gefitinib was reported in the cases of response to initial treatment with gefitinib. We retrospectively evaluated the efficacy and safety of treatment with EGFR TK-Is re-challenge in patients with advanced and recurrent NSCLC in our institute. Methods and Result: Forty-four patients with advanced and recurrent NSCLC received EGFR TK-Is re-challenge from October 2003 to February 2013 in our institute. Twenty-four patients were treated with erlotinib after failure of the initial gefitinib treatment. Male/female = 9/15; Median age was 69 years; smoker/ non-smoker = 7/17; ECOG PS 0/1/2/3 = 17/3/3/1. Response rate(RR) was 30.4% and disease control rate (DCR) was 73.9%. Grade3 rash (4.2%) and grade3 fatigue (4.2%) were observed. Dose reduction was needed in seven patients. Seventeen patients were re-treated with gefitinib after failure of the initial gefitinib treatment. Male/female = 2/ 15; Median age was 67 years; smoker/non-smoker = 3/14; ECOG PS 0/1/2/3 = 6/9/2/0. Response rate(RR) was 21.4% and disease control rate (DCR) was 85.7%. Grade3 interstitial lung disease (5.9%) and grade3 rush (5.9%) were observed. Dose reduction was needed in three patients. Three patients were re-treated with erlotinib after failure of the initial erlotinib treatment. Male/female = 2/1; smoker/non-smoker = 2/1; ECOG PS 0/1/2/3 = 0/3/0/0; CR/PR/SD/PD = 0/0/1/2. Dose reduction was needed in one patient. Conclusion: Treatment with EGFR TK-Is re-challenge is effective and well-tolerated.